T. Rowe Price Associates
GNMX

T. Rowe Price Associates’s Aevi Genomic Medicine Inc GNMX Stock Holding History

T. Rowe Price Associates’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-276,250
Closed -$307K – 2621
2018
Q2 		$307K Sell
276,250
-867,560
-76% -$1.32M ﹤0.01% 2339
2018
Q1 		$2.3M Buy
+1,143,810
New +$2.15M ﹤0.01% 1542
2017
Q1 		– Sell
-760,167
Closed -$3.94M – 2609
2016
Q4 		$3.94M Sell
760,167
-3,700
-0.5% -$19.5K ﹤0.01% 1448
2016
Q3 		$4.25M Buy
763,867
+2,667
+0.4% +$15.2K ﹤0.01% 1443
2016
Q2 		$4.22M Sell
761,200
-3,800
-0.5% -$20K ﹤0.01% 1420
2016
Q1 		$3.37M Hold
765,000
– – ﹤0.01% 1445
2015
Q4 		$4.61M Buy
+765,000
New +$5.19M ﹤0.01% 1428

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's GNMX Position: Q3 2018 in Review

T. Rowe Price Associates sold out of Aevi Genomic Medicine Inc (GNMX) in Q3 2018, closing a stake of 276,250 shares — an estimated $307K sold.

T. Rowe Price Associates first reported a position in GNMX in Q4 2015 and held it in 7 quarters. The position peaked at $4.61M in Q4 2015. 44 funds tracked by Wall St. Rank hold GNMX as of Q3 2018.

  • T. Rowe Price Associates reported no remaining Aevi Genomic Medicine Inc position as of Q3 2018 after selling out during the quarter.
  • T. Rowe Price Associates sold 276,250 Aevi Genomic Medicine Inc shares in Q3 2018, an estimated $307K.
  • T. Rowe Price Associates first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 7 quarters.
  • T. Rowe Price Associates's Aevi Genomic Medicine Inc position peaked at $4.61M in Q4 2015.
  • 44 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q3 2018.

Based on T. Rowe Price Associates's 13F filing for Q3 2018, filed 14 Nov 2018.